

# Otakar Capoun

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3512073/otakar-capoun-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

2,405

citations

14

h-index

30

g-index

30

ext. papers

3,511

ext. citations

4.6

avg, IF

4.77

L-index

#	Paper	IF	Citations
28	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>European Urology</i> , <b>2017</b> , 71, 447-461	10.2	1199
27	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta/T1 and Carcinoma In Situ) - 2019 Update. <i>European Urology</i> , <b>2019</b> , 76, 639-657	10.2	531
26	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , <b>2021</b> , 79, 62-79	10.2	176
25	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> <b>2017</b> , 72, 801-813	10.2	124
24	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , <b>2021</b> , 79, 480-488	10.2	51
23	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). <i>European Urology</i> , <b>2021</b> ,	10.2	51
22	MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. <i>Neoplasma</i> , <b>2016</b> , 63, 799-808	3.3	40
21	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , <b>2020</b> , 6, 479-489	5.1	39
20	Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. <i>Urologia Internationalis</i> , <b>2015</b> , 95, 56-64	1.9	29
19	Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. <i>Urologia Internationalis</i> , <b>2016</b> , 96, 25-31	1.9	26
18	The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. <i>Urologia Internationalis</i> , <b>2014</b> , 92, 150-6	1.9	23
17	Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , <b>2017</b> , 161, 272-280	1.7	16
16	Prevention of bladder cancer incidence and recurrence: tobacco use. <i>Current Opinion in Urology</i> , <b>2018</b> , 28, 80-87	2.8	15
15	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 182-191	6.7	15
14	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 440-448	2.8	14
13	Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of Prostate Cancer. <i>Urologia Internationalis</i> , <b>2015</b> , 95, 429-35	1.9	10
12	Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest <sup>®</sup> System for Detection of Circulating Tumor Cells. <i>Anticancer Research</i> , <b>2016</b> , 36, 2019-26	2.3	9

11	Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A. <i>Anticancer Research</i> , <b>2018</b> , 38, 239-246	2.3	7
10	The characterization of four gene expression analysis in circulating tumor cells made by Multiplex-PCR from the AdnaTest kit on the lab-on-a-chip Agilent DNA 1000 platform. <i>Biochimica Medica</i> , <b>2016</b> , 26, 103-113	2.5	6
9	Prognostic Importance of Vitamins A, E and Retinol-binding Protein 4 in Renal Cell Carcinoma Patients. <i>Anticancer Research</i> , <b>2017</b> , 37, 3801-3806	2.3	6
8	Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 924, 97-100	3.6	4
7	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , <b>2018</b> , 4, 525-528	5.1	4
6	Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2018</b> , 22, 381-390	4.5	3
5	HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study. <i>Scientific Reports</i> , <b>2020</b> , 10, 14365	4.9	3
4	Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer. <i>BMC Urology</i> , <b>2020</b> , 20, 144	2.2	2
3	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.. <i>European Urology</i> , <b>2022</b> ,	10.2	2
2	Surgical treatment of urinary bladder cancer. <i>Onkologie (Czech Republic)</i> , <b>2019</b> , 13, 195-200	0.1	
1	The meaning of sampling density in multiple repeat prostate biopsies. <i>Central European Journal of Urology</i> , <b>2016</b> , 69, 347-352	0.9	